Tags

Type your tag names separated by a space and hit enter

Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
Menopause 2009 Mar-Apr; 16(2):357-66M

Abstract

OBJECTIVE

To compare the effects of enriched ethyl-eicosapentaenoic acid (E-EPA) omega-3 fatty acid supplementation with those of placebo on hot flashes (HFs) and quality of life among middle-aged women.

METHODS

Women were considered for participation if they were between 40 and 55 years of age and had moderate to severe psychological distress. A total of 120 women were randomly assigned to E-EPA or placebo for 8 weeks. Only women with HFs were included in this analysis (E-EPA, n = 45; placebo, n = 46). Outcomes were changes from baseline to week 8 postintervention regarding hot flash (HF) frequency (number of HFs per day), intensity and score (frequency x intensity), and Menopause-specific Quality of Life questionnaire scores.

RESULTS

At baseline, the average number of HFs was 2.8 per day. After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group. There was no difference in the change in HF intensity between groups. Frequency of HFs declined by a mean of 1.58 per day (95% CI, -2.18 to -0.98) in the E-EPA group and by 0.50 per day (95% CI, -1.20 to 0.20) in the placebo group. The odds of being a responder among those taking E-EPA were about three times greater than among those taking placebo (odds ratio, 2.70; 95% CI, 1.03-7.03; P = 0.04). Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them.

CONCLUSIONS

Supplementation with E-EPA omega-3 fatty acid reduced HF frequency and improved the HF score relative to placebo. These results need to be confirmed by a clinical trial specifically designed to evaluate HFs in more symptomatic women.

Authors+Show Affiliations

Saint-François d'Assise Hospital, Centre Hospitalier Universitaire de Québec, Québec, Canada. michel.lucas@crchul.ulaval.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19034052

Citation

Lucas, Michel, et al. "Effects of Ethyl-eicosapentaenoic Acid Omega-3 Fatty Acid Supplementation On Hot Flashes and Quality of Life Among Middle-aged Women: a Double-blind, Placebo-controlled, Randomized Clinical Trial." Menopause (New York, N.Y.), vol. 16, no. 2, 2009, pp. 357-66.
Lucas M, Asselin G, Mérette C, et al. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause. 2009;16(2):357-66.
Lucas, M., Asselin, G., Mérette, C., Poulin, M. J., & Dodin, S. (2009). Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause (New York, N.Y.), 16(2), pp. 357-66. doi:10.1097/gme.0b013e3181865386.
Lucas M, et al. Effects of Ethyl-eicosapentaenoic Acid Omega-3 Fatty Acid Supplementation On Hot Flashes and Quality of Life Among Middle-aged Women: a Double-blind, Placebo-controlled, Randomized Clinical Trial. Menopause. 2009;16(2):357-66. PubMed PMID: 19034052.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. AU - Lucas,Michel, AU - Asselin,Geneviève, AU - Mérette,Chantal, AU - Poulin,Marie-Josée, AU - Dodin,Sylvie, PY - 2008/11/27/pubmed PY - 2009/10/29/medline PY - 2008/11/27/entrez SP - 357 EP - 66 JF - Menopause (New York, N.Y.) JO - Menopause VL - 16 IS - 2 N2 - OBJECTIVE: To compare the effects of enriched ethyl-eicosapentaenoic acid (E-EPA) omega-3 fatty acid supplementation with those of placebo on hot flashes (HFs) and quality of life among middle-aged women. METHODS: Women were considered for participation if they were between 40 and 55 years of age and had moderate to severe psychological distress. A total of 120 women were randomly assigned to E-EPA or placebo for 8 weeks. Only women with HFs were included in this analysis (E-EPA, n = 45; placebo, n = 46). Outcomes were changes from baseline to week 8 postintervention regarding hot flash (HF) frequency (number of HFs per day), intensity and score (frequency x intensity), and Menopause-specific Quality of Life questionnaire scores. RESULTS: At baseline, the average number of HFs was 2.8 per day. After 8 weeks, HF frequency and score decreased significantly in the E-EPA group compared with the placebo group. There was no difference in the change in HF intensity between groups. Frequency of HFs declined by a mean of 1.58 per day (95% CI, -2.18 to -0.98) in the E-EPA group and by 0.50 per day (95% CI, -1.20 to 0.20) in the placebo group. The odds of being a responder among those taking E-EPA were about three times greater than among those taking placebo (odds ratio, 2.70; 95% CI, 1.03-7.03; P = 0.04). Menopause-Specific Quality of Life scores improved significantly over time in both groups but no significant differences were noted between them. CONCLUSIONS: Supplementation with E-EPA omega-3 fatty acid reduced HF frequency and improved the HF score relative to placebo. These results need to be confirmed by a clinical trial specifically designed to evaluate HFs in more symptomatic women. SN - 1530-0374 UR - https://www.unboundmedicine.com/medline/citation/19034052/Effects_of_ethyl_eicosapentaenoic_acid_omega_3_fatty_acid_supplementation_on_hot_flashes_and_quality_of_life_among_middle_aged_women:_a_double_blind_placebo_controlled_randomized_clinical_trial_ L2 - http://Insights.ovid.com/pubmed?pmid=19034052 DB - PRIME DP - Unbound Medicine ER -